Loading...
Biologic therapies have demonstrated efficacy for controlling psoriatic disease, but some have been withdrawn and others never make it to market because of safety issues. Briakinumab is a monoclonal antibody against the p40 molecule shared by interleukin-12 and interleukin-23. In a double-blinded trial, investigators randomized 317 patients with moderate-to-severe psoriasis to briakinumab (weeks 1 and 4, 200 mg; 100 mg every 4 weeks thereafter) or to methotrexate (5 mg/week initially, up to 25 mg/week); participants also received folic acid, 5 mg/week. Primary endpoints were improvement of at least 75% in the psoriasis area-and-severity index (PASI) score and scores indicating no or minimal disease on the physician's global assessment (PGA)…